吉利德科学与LEO Pharma合作开发炎症性疾病项目

格隆汇
13 Jan

格隆汇1月13日|吉利德科学上周六表示,已与丹麦LEO Pharma达成合作,开发治疗炎症性疾病患者的项目。LEO Pharma将有资格获得高达17亿美元的付款,其中包括吉利德支付的2.5亿美元预付款。作为回报,吉利德将拥有在全球开发、制造和商业化小分子口服 STAT6项目的权利。声明称,针对STAT6的临床前研究已显示出治疗广泛炎症疾病(如特应性皮炎、哮喘和COPD)的潜力。此次交易预计将使吉利...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10